Rheumatoid Arthritis Clinical Trials

Showing 29701-29720 of 47,334 trials

A Phase I-Ib/II Study to Determine the Maximum Tolerated Dose (MTD) of AUY922 Alone and in Combination With Bortezomib, With or Without Dexamethasone, in Patients With Relapsed or Refractory Multiple Myeloma.

NCT00708292

This is a Phase I-Ib/II, open-label, multicenter study of AUY922 administered intravenously in patients with multiple myeloma to determine the maximum tolerated dose. The Phase II part will investigate the efficacy of AUY922 in patients with multiple myeloma. Additionally, the study includes a Phase Ib combination part of AUY922 administered in combination with bortezomib, to determine the maximum tolerated dose of the combination drugs in patients with multiple myeloma.

Relapsed or Refractory Multiple Myeloma

Novartis Pharmaceuticals29 participantsStarted Jul 2008

Scottsdale, Arizona, United States • San Antonio, Texas, United States • Melbourne, Australia +6 more locations

COMPLETEDNA

Treatment Protocols for Patients With Symptomatic Oral Lichen Planus

NCT04673916

The primary objective of this study was to compare the therapeutic efficacy of clobetasol propionate 0.05% oral gel versus an anti-inflammatory mouthwash in an oral solution for the management of patients suffering from symptomatic OLP. The secondary objective was to analyze which one of the two treatments induced a greater risk of developing side effects.

Lichen Planus, OralPreneoplastic Condition

University of Messina61 participantsStarted Jun 2019

Messina, Italy

Not Yet RecruitingEARLY Phase 1

A Study of Humanized BCMA-targeted CAR-T Cells Therapy for Refractory/Relapsed Multiple Myeloma

NCT04670055

Clinical Trial for the safety and efficacy of humanized BCMA-targeted CAR-T cells therapy for refractory/relapsed multiple myeloma

Relapse Multiple MyelomaRefractory Multiple Myeloma

Zhejiang University50 participantsStarted Jan 2021

Hangzhou, Zhejiang, China

A Phase I-Ib/II Study to Determine the Maximum Tolerated Dose (MTD) of AUY922 Alone and in Combination With Bortezomib, With or Without Dexamethasone, in Patients With Relapsed or Refractory Multiple Myeloma.

Treatment Protocols for Patients With Symptomatic Oral Lichen Planus

A Study of Humanized BCMA-targeted CAR-T Cells Therapy for Refractory/Relapsed Multiple Myeloma

Related Searches

Exparel Use in Bilateral TAP Blocks for Postoperative Pain Control

Induction Chemotherapy Plus Chemoradiotherapy With or Without Aspirin in High Risk Rectal Cancer

Long-term Telerehabilitation for Patients With Stroke

Temocillin Versus Carbapenems for Urinary Tract Infection Due to ESBL-producing Enterobacteriaceae

Efficacy and Safety of Patupilone in Men (≥18 Years) With Metastatic Hormone Refractory Prostate Cancer

CLINICAL EFFECT OF BOTULINUM TOXIN TYPE A IN TREATMENT OF SPASTICITY

Efficacy, Safety and Tolerability of BYM338 in Patients With Sporadic Inclusion Body Myositis

Understanding Non-radiotherapy-based Development of Trismus

Cognitive Side Effects of Commonly Prescribed Medications in Pediatric Migraine

Efficacy and Safety of AEB071 Plus Tacrolimus (Converted to Mycophenolic Acid After 3 Months), in Renal Transplant Patients

Abnormal Uterine Bleeding and Progestin-only Contraceptives

Effectiveness of Platelet-rich Plasma for Treatment of Trigger Finger

Mesenchymal Stem Cells and Amniotic Membrane Composite for Supraspinatus Tendon Repair Augmentation

The Economic Impact of Clinical Pharmacist Involvement in the Public Procurement for Medicines and in the Drug and Therapeutics Committee

Natural History of Nonspecific Pleuritis Diagnosed After Video-assisted-thoracoscopic-surgery

Oral Processing Behavior of Gluten-free and Gluten-containing Breads

Infection Tracking in Travellers. The Project Aims to Identify Profiles of Travel-associated Illness and to Follow up on Long-term Sequelae of Arboviral Infections and Malaria